Hemostatic alterations in liver disease: A review on pathophysiology, clinical consequences, and treatment

Digestive Surgery

Volumn 24, Issue 4, 2007, Pages 250-258

  Lisman, Ton ^a,b   Leebeek, Frank W G ^c  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Fibrinolytic system; Hemostasis testing; Hemostatic abnormalities; Hemostatic dysbalance; Primary hemostasis; Secondary hemostasis

Indexed keywords

APROTININ; DESMOPRESSIN; FRESH FROZEN PLASMA; RECOMBINANT BLOOD CLOTTING FACTOR 7A; TRANEXAMIC ACID;

BLEEDING; BLOOD VESSEL RUPTURE; CHRONIC DISEASE; CONFERENCE PAPER; FIBRINOLYSIS; HEMOSTASIS; HEPATIC ARTERY; HUMAN; HYPERCOAGULABILITY; LIVER DISEASE; LIVER FAILURE; LIVER TRANSPLANTATION; PORTAL HYPERTENSION; PORTAL VEIN THROMBOSIS; VARICOSIS; VASCULAR DISEASE;

BLOOD COAGULATION DISORDERS; BLOOD COAGULATION TESTS; HEMOSTASIS; HUMANS; LIVER DISEASES; LIVER FAILURE; LIVER FAILURE, ACUTE; PLASMA; TREATMENT OUTCOME;

EID: 34547416114     PISSN: 02534886     EISSN: None     Source Type: Journal    
DOI: 10.1159/000103655     Document Type: Conference Paper

References (62)

1. Aster RH: Pooling of platelets in the spleen: role in the pathogenesis of 'hypersplenic' thrombocytopenia. J Clin Invest 1966;45:645-657.
2. Goulis J, Chau TN, Jordan S, Mehta AB, Watkinson A, Rolles K, Burroughs AK: Thrombopoietin concentrations are low in patients with cirrhosis and thrombocytopenia and are restored after orthotopic liver transplantation. Gut 1999;44:754-758.
3. Kajihara M, Kato S, Okazaki Y, Kawakami Y, Ishii H, Ikeda Y, Kuwana M: A role of auto-antibody-mediated platelet destruction in thrombocytopenia in patients with cirrhosis. Hepatology 2003;37:1267-1276.
4. Levine RF, Spivak JL, Meagher RC, Sieber F: Effect of ethanol on thrombopoiesis. Br J Haematol 1986;62:345-354.
5. Ben Ari Z, Osman E, Hutton RA, Burroughs AK: Disseminated intravascular coagulation in liver cirrhosis: fact or fiction? Am J Gastroenterol 1999;94:2977-2982.
6. Escolar G, Cases A, Vinas M, Pino M, Calls J, Cirera I, Ordinas A: Evaluation of acquired platelet dysfunctions in uremic and cirrhotic patients using the platelet function analyzer (PFA-100): influence of hematocrit elevation. Haematologica 1999;84:614-619.
7. Laffi G, Marra F, Gresele P, Romagnoli P, Palermo A, Bartolini O, Simoni A, Orlandi L, Selli ML, Nenci GG: Evidence for a storage pool defect in platelets from cirrhotic patients with defective aggregation. Gastroenterology 1992;103:641-646.
8. Laffi G, Marra F, Failli P, Ruggiero M, Cecchi E, Carloni V, Giotti A, Gentilini P: Defective signal transduction in platelets from cirrhotics is associated with increased cyclic nucleotides. Gastroenterology 1993;105:148-156.
9. Laffi G, Cominelli F, Ruggiero M, Fedi S, Chiarugi VP, La Villa G, Pinzani M, Gentilini P: Altered platelet function in cirrhosis of the liver: impairment of inositol lipid and arachidonic acid metabolism in response to agonists. Hepatology 1988;8:1620-1626.
10. Pasche B, Ouimet H, Francis S, Loscalzo J: Structural changes in platelet glycoprotein IIb/IIIa by plasmin: determinants and functional consequences. Blood 1994;83:404-414.
11. Desai K, Mistry P, Bagget C, Burroughs AK, Bellamy MF, Owen JS: Inhibition of platelet aggregation by abnormal high density lipoprotein particles in plasma from patients with hepatic cirrhosis. Lancet 1989;1:693-695.
12. Turitto VT, Baumgartner HR: Platelet interaction with subendothelium in a perfusion system: physical role of red blood cells. Microvasc Res 1975;9:335-344.
13. Cahill PA, Redmond EM, Sitzmann JV: Endothelial dysfunction in cirrhosis and portal hypertension. Pharmacol Ther 2001;89:273-293.
14. Lisman T, Adelmeijer J, de Groot PG, Janssen HL, Leebeek FW: No evidence for an intrinsic platelet defect in patients with liver cirrhosis - studies under flow conditions. J Thromb Haemost 2006;4:2070-2072.
15. Tripodi A, Primignani M, Chantarangkul V, Clerici M, Dell'era A, Fabris F, Salerno F, Mannucci PM: Thrombin generation in patients with cirrhosis: the role of platelets. Hepatology 2006;44:440-445.
16. Ferro D, Quintarelli C, Lattuada A, Leo R, Alessandroni M, Mannucci PM, Violi F: High plasma levels of von Willebrand factor as a marker of endothelial perturbation in cirrhosis: relationship to endotoxemia. Hepatology 1996;23:1377-1383.
17. Hollestelle MJ, Geertzen HGM, Straatsburg IH, van Gulik TM, van Mourik JA: Factor VIII expression in liver disease. Thromb Haemost 2004;91;267-275.
18. Lisman T, Bongers TN, Adelmeijer J, Janssen HL, de Maat MP, de Groot PG, Leebeek FW: Elevated levels of von Willebrand factor in cirrhosis support platelet adhesion despite reduced functional capacity. Hepatology 2006;44:53-61.
19. Blanchard RA, Furie BC, Jorgensen M, Kruger SF, Furie B: Acquired vitamin K-dependent carboxylation deficiency in liver disease. N Engl J Med 1981;305:242-248.
20. Martinez J, MacDonald KA, Palascak JE: The role of sialic acid in the dysfibrinogenemia associated with liver disease: distribution of sialic acid on the constituent chains. Blood 1983;61:1196-1202.
21. Bontempo FA, Lewis JH, Gorenc TJ, Spero JA, Ragni MV, Scott JP, Starzl TE: Liver transplantation in hemophilia A. Blood 1987;69:1721-1724.
22. Hollestelle MJ, Poyck PP, Hollestelle JM, Marsman HA, Mourik JA, Gulik TM: Extrahepatic factor VIII expression in porcine fulminant hepatic failure. J Thromb Haemost 2005;3:2274-2280.
23. Jacquemin M, Neyrinck A, Hermanns MI, Lavend'homme R, Rega F, Saint-Remy JM, Peerlinck K, Van RD, Kirkpatrick CJ: FVIII production by human lung microvascular endothelial cells. Blood 2006;108:515-517.
24. Lisman T, Leebeek FWG, de Groot PG: Haemostatic abnormalities in patients with liver disease. J Hepatol 2002;37:280-287.
25. Bajaj MS, Kuppuswamy MN, Saito H, Spitzer SG, Bajaj SP: Cultured normal human hepatocytes do not synthesize lipoprotein-associated coagulation inhibitor: evidence that endothelium is the principal site of its synthesis. Proc Natl Acad Sci USA 1990;87:8869-8873.
26. Oksuzoglu G, Simsek H, Haznedaroglu IC, Kirazli S: Tissue factor pathway inhibitor concentrations in cirrhotic patients with and without portal vein thrombosis. Am J Gastroenterol 1997;92:303-306.
27. Stein SF, Harker LA: Kinetic and functional studies of platelets, fibrinogen, and plasminogen in patients with hepatic cirrhosis. J Lab Clin Med 1982;99:217-230.
28. Lisman T, Leebeek FW, Mosnier LO, Bouma BN, Meijers JC, Janssen HL, Nieuwenhuis HK, de Groot PG: Thrombin-activatable fibrinolysis inhibitor deficiency in cirrhosis is not associated with increased plasma fibrinolysis. Gastroenterology 2001;121:131-139.
29. Biland L, Duckert F, Prisender S, Nyman D: Quantitative estimation of coagulation factors in liver disease. The diagnostic and prognostic value of factor XIII, factor V and plasminogen. Thromb Haemost 1978;39:646-656.
30. Leiper K, Croll A, Booth NA, Moore NR, Sinclair T, Bennett B: Tissue plasminogen activator, plasminogen activator inhibitors, and activator-inhibitor complex in liver disease. J Clin Pathol 1994;47:214-217.
31. Leebeek FWG, Kluft C, Knot EAR, de Maat MPM, Wilson JHP: A shift in balance between profibrinolytic and antifibrinolytic factors causes enhanced fibrinolysis in cirrhosis. Gastroenterology 1991;101:1382-1390.
32. Pernambuco JR, Langley PG, Hughes RD, Izumi S, Williams R: Activation of the fibrinolytic system in patients with fulminant liver failure. Hepatology 1993;18:1350-1356.
33. Leebeek FWG: Hyperfibrinolysis in liver cirrhosis; in Greenwaldt P (ed): Fibrinolysis in Disease. Boca Raton, CRC Press, 1995, pp 194-201.
34. Violi F, Ferro D, Basili S, Quintarelli C, Musca A, Cordova C, Balsano F, the CALC Group: Hyperfibrinolysis resulting from clotting activation in patients with different degrees of cirrhosis. Hepatology 1993;17:78-83.
35. Oka K, Tanaka K: Intravascular coagulation in autopsy cases with liver diseases. Thromb Haemost 1979;42:564-570.
36. Colucci M, Binetti BM, Branca MG, Clerici C, Morelli A, Semeraro N, Gresele P: Deficiency of thrombin activatable fibrinolysis inhibitor in cirrhosis is associated with increased plasma fibrinolysis. Hepatology 2003;38:230-237.
37. Segal H, Cottam S, Potter D, Hunt BJ: Coagulation and fibrinolysis in primary biliary cirrhosis compared with other liver disease and during orthotopic liver transplantation. Hepatology 1997;25:683-688.
38. Amitrano L, Brancaccio V, Guardascione MA, Margaglione M, Iannaccone L, D'Andrea G, Marmo R, Ames PR, Balzano A: Inherited coagulation disorders in cirrhotic patients with portal vein thrombosis. Hepatology 2000;31:345-348.
39. Joist JH, George JN: Hemostatic abnormalities in liver and renal disease; in Colman RW, Hirsh J, Marder VJ, Clowes AE, George JN (eds): Hemostasis and Thrombosis. Philadelphia, Lippincott Williams & Wilkins, 2001, pp 955-973.
40. Thalheimer U, Triantos CK, Samonakis DN, Patch D, Burroughs AK: Infection, coagulation, and variceal bleeding in cirrhosis. Gut 2005;54:556-563.
41. Reitsma PH, Branger J, Van Den BB, Weijer S, van der PT, Meijers JC: Procoagulant protein levels are differentially increased during human endotoxemia. J Thromb Haemost 2003;1:1019-1023.
42. Caldwell SH, Hoffman M, Lisman T, Macik BG, Northup PG, Reddy KR, Tripodi A, Sanyal AJ: Coagulation disorders and hemostasis in liver disease: pathophysiology and critical assessment of current management. Hepatology 2006;44:1039-1046.
43. Tripodi A, Salerno F, Chantarangkul V, Clerici M, Cazzaniga M, Primignani M, Mannucci PM: Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests. Hepatology 2005;41:553-558.
44. Mannucci PM: Abnormal hemostasis tests and bleeding in chronic liver disease: Are they related? No. J Thromb Haemost 2006;4:721-723.
45. Lisman T, Caldwell SH, Leebeek FWG, Porte RJ: Hemostasis in chronic liver disease - Is chronic liver disease associated with a bleeding diathesis? J Thromb Haemost 2006;4:2059-2060.
46. Sharara AI, Rockey DC: Gastroesophageal variceal hemorrhage. N Engl J Med 2001;345:669-681.
47. De Boer MT, Molenaar IQ, Hendriks HG, Slooff MJ, Porte RJ: Minimizing blood loss in liver transplantation: progress through research and evolution of techniques. Dig Surg 2005;22:265-275.
48. Trotter JF, Brimhall B, Arjal R, Phillips C: Specific laboratory methodologies achieve higher model for end-stage liver disease (MELD) scores for patients listed for liver transplantation. Liver Transpl 2004;10:995-1000.
49. Robert A, Chazouilleres O: Prothrombin time in liver failure: time, ratio, activity percentage, or international normalized ratio? Hepatology 1996;24:1392-1394.
50. O'Shaughnessy DF, Atterbury C, Bolton MP, Murphy M, Thomas D, Yates S, Williamson LM: Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant. Br J Haematol 2004;126:11-28.
51. Youssef WI, Salazar F, Dasarathy S, Beddow T, Mullen KD: Role of fresh-frozen plasma infusion in correction of coagulopathy of chronic liver disease: a dual phase study. Am J Gastroenterol 2003;98:1391-1394.
52. Bravo AA, Sheth SG, Chopra S: Liver biopsy. N Engl J Med 2001;344:495-500.
53. Burroughs AK, Matthews K, Qadiri M, Thomas N, Kernoff P, Tuddenham E, McIntyre N: Desmopressin and bleeding time in patients with cirrhosis. Br Med J (Clin Res Ed) 1985;291:1377-1381.
54. De Franchis R, Arcidiacono PG, Carpinelli L, Andreoni B, Cestari L, Brunati S, Zambelli A, Battaglia G, Mannucci PM: Randomized controlled trial of desmopressin plus terlipressin versus terlipressin alone for the treatment of acute variceal hemorrhage in cirrhotic patients: a multicenter, doubleblind study. New Italian Endoscopic Club. Hepatology 1993;18:1102-1107.
55. Wong AY, Irwin MG, Hui TW, Fung SK, Fan ST, Ma ES: Desmopressin does not decrease blood loss and transfusion requirements in patients undergoing hepatectomy. Can J Anaesth 2003;50:14-20.
56. Pivalizza EG, Warters RD, Gebhard R: Desmopressin before liver transplantation. Can J Anaesth 2003:50:748-749.
57. Porte RJ, Molenaar IQ, Begliomini B, Groenland TH, Januszkiewicz A, Lindgren L, Palareti G, Hermans J, Terpstra OT: Aprotinin and transfusion requirements in orthotopic liver transplantation: a multicentre randomised double-blind study. EMSALT Study Group. Lancet 2000;355:1303-1309.
58. Boylan JF, Klinck JR, Sandler AN, Arellano R, Greig PD, Nierenberg H, Roger SL, Glynn MF: Tranexamic acid reduces blood loss, transfusion requirements, and coagulation factor use in primary orthotopic liver transplantation. Anesthesiology 1996;85:1043-1048.
59. Mangano DT, Tudor IC, Dietzel C: The risk associated with aprotinin in cardiac surgery. N Engl J Med 2006;354:353-365.
60. Hendriks HG, Meijer K, de Wolf JT, Klompmaker IJ, Porte RJ, de Kam PJ, Hagenaars AJ, Melsen T, Slooff MJ, van der Meer J: Reduced transfusion requirements by recombinant factor VIIa in orthotopic liver transplantation: a pilot study. Transplantation 2001;71:402-405.
61. Planinsic RM, van der MJ, Testa G, Grande L, Candela A, Porte RJ, Ghobrial RM, Isoniemi H, Schelde PB, Erhardtsen E, Klintmalm G, Emre S: Safety and efficacy of a single bolus administration of recombinant factor VIIa in liver transplantation due to chronic liver disease. Liver Transpl 2005;11:895-900.
62. Lodge JP, Jonas S, Jones RM, Olausson M, Mir-Pallardo J, Soefelt S, Garcia-Valdecasas JC, McAlister V, Mirza DF: Efficacy and safety of repeated perioperative doses of recombinant factor VIIa in liver transplantation. Liver Transpl 2005;11:973-979.